glp-1 日本 東京で行われたGLP-1 National Conferenceに参加してきました。 糖尿病治療薬である経口GLP-1受容体作動薬について、 「どうすれば効果を最大限に、そして副作用を最小限にできるか」 実臨床に直結するお話を多く学ぶことができました。 糖尿病治療の選択肢が広がる中で なぜ"やせ薬"GLP-1は日本で批判されるのか メディアの偏向報道､専門医の縄張り意識…医師が明かす根本的な問題 | ライフ |

A pre-specified threshold of IGF-1 Z-score of 3 was included in the protocol as a trigger to decrease tesamorelin dose to 1mg, along with a dummy dose-reduction in the placebo group, but this was not required for any participant

Figures 4(a) and (b))

Type 1 diabetic patients require daily doses of insulin for life

Therapeutic potential of targeting cathepsin S in pulmonary fibrosis

From the aforementioned methods, DW-ASL and multi-TE ASL are the most used in clinical research (Lee et al., 1999

Data availability The datasets analyzed during this study are not publicly available for ethical reasons but can be obtained from the corresponding author upon reasonable request